TICKERNERD
Menu
SIBNSIBNHealthcare · Medical Devices

SIBN Stock Forecast: SI-BONE, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$20
+2.46% on the day

The 9 Wall Street analysts covering SI-BONE, Inc. hold a median 12-month price target of $25 — +25.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 22 Aug 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$885.2M
Ticker Nerd rank
72 / 100
Median analyst target
$25
Analysts covering
9
Total return, dividends reinvested
1W
+5.4%
1M
+17.1%
YTD
+1.2%
1Y
+27.6%
From 52W high
−6.7%
From 52W low
+71.9%
$12
$21
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SIBN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SI-BONE, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
81
Quality
81
Volatility
75
Growth
62
Accruals
61
Momentum
54
Value
51
Size
47
Issuance
28

Revisions (81): Analysts have, on balance, been raising their forecasts.

Issuance (28): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SIBN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SIBN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26SIBNHigh $32Median $25Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $20Median $25High $32

The green dot is the last close — the median target sits +25.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
4 Aug 2026TD CowenMaintainsBuy$18 → $20
4 Aug 2026Truist SecuritiesReiteratesBuy$21 → $23
4 Aug 2026UBSMaintainsBuy$24 → $25
28 July 2026UBSInitiatesBuy$24
16 July 2026Truist SecuritiesMaintainsBuy—
16 July 2026Truist SecuritiesMaintainsBuy$18 → $21
12 May 2026TD CowenMaintainsBuy$22 → $18
12 May 2026TD CowenMaintainsBuy—
12 May 2026Truist SecuritiesReiteratesBuy$20 → $18
12 May 2026Truist SecuritiesReiteratesBuy—
15 Apr 2026Truist SecuritiesMaintainsBuy—
24 Feb 2026TD CowenMaintainsBuy—
24 Feb 2026Truist SecuritiesReiteratesBuy—
27 Jan 2026TD CowenInitiatesBuy—
18 Dec 2025Truist SecuritiesMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
16 Dec 2025NeedhamMaintainsBuy—
2 Dec 2025Morgan StanleyMaintainsOverweight—
15 Oct 2025Truist SecuritiesMaintainsBuy—
5 Aug 2025Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SIBN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

SIBN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
5
Analysts cutting
1
Fundamentals

SI-BONE, Inc. (SIBN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−45.4×

Cheaper than 98% of US stocks

Price / sales
4.2×

Cheaper than 31% of US stocks

Price / book
4.9×

Cheaper than 23% of US stocks

EV / EBITDA
−69.9×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
15.2%

Higher than 63% of US stocks

Earnings growth (YoY)
15.2%

Higher than 54% of US stocks

Gross margin
79.5%

Higher than 90% of US stocks

Operating margin
−8.6%

Higher than 25% of US stocks

Net margin
−6.9%

Higher than 22% of US stocks

Returns & dividend
Return on equity
−8.3%

Higher than 37% of US stocks

Return on assets
−4.6%

Higher than 32% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

SIBN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
SIBNSI-BONE, Inc.$885.2M
72
INMDInMode Ltd.$865.7M
76
CBLLCeribell, Inc.$897.7M
32
BBNXBeta Bionics, Inc.$838.7M
36
VREXVarex Imaging Corp.$775.9M
80
QDELQuidelOrtho Corp.$1.0B
35
AHCOAdaptHealth Corp.$765.2M
51

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SI-BONE, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SIBN news & analysis

Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?

Zacks Investment Research · 6 Aug 2026positive

Zacks reports that the consensus price target for Si-Bone (SIBN) implies roughly 38.6% upside potential, while noting that price targets are generally not highly reliable. The article points to an upward trend in earnings estimate revisions as a potential positive indicator for the stock in the near term.

Why it matters — A SIBN watcher would care because rising earnings estimate revisions could signal improving expectations among analysts covering the company.

SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call Transcript

Seeking Alpha · 4 Aug 2026neutral

SI-BONE, Inc. held its Q2 2026 earnings call, and Seeking Alpha published the full transcript of that call.

Why it matters — A transcript of the Q2 2026 earnings call gives SIBN watchers direct access to management's commentary on the company's latest quarterly results.

Si-Bone (SIBN) Reports Q2 Loss, Tops Revenue Estimates

Zacks Investment Research · 3 Aug 2026positive

Si-Bone (SIBN) reported a second-quarter loss of $0.09 per share, narrower than both the Zacks Consensus Estimate of a $0.15 loss and the $0.14 loss reported a year ago. The company also topped revenue estimates for the quarter.

Why it matters — The smaller-than-expected loss and revenue beat suggest Si-Bone's financial performance is improving relative to analyst expectations.

SiBone Q2 Earnings Call Highlights

MarketBeat · 3 Aug 2026positive

SI-BONE reported second-quarter 2026 revenue growth of 15.2% and narrowed its net loss. The results were driven by increased procedure volumes across its U.S. business and higher international demand for its expanded product portfolio.

Why it matters — For SIBN watchers, the revenue growth and narrower net loss reflect strengthening demand and an improving cost profile in the company's core business.

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance

GlobeNewsWire · 3 Aug 2026positive

SI-BONE, Inc. reported financial results for the second quarter of 2026, citing approximately 15% worldwide revenue growth, an approximately 178% increase in adjusted EBITDA, and an approximately 19% increase in its U.S. physician base. The company also raised its guidance for 2026.

Why it matters — The reported revenue growth, improved profitability, expanded physician base, and raised guidance signal strengthening operational performance at SI-BONE.

FAQ

Frequently asked questions about SIBN stock

What is the SIBN stock price forecast for 2026-2027?

The 9 Wall Street analysts covering SI-BONE, Inc. have a median 12-month price target of $25, with estimates ranging from $20 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SIBN stock a buy right now?

Of the 9 analysts covering SI-BONE, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SI-BONE, Inc. 72 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SIBN?

As at 22 Aug 2026, SI-BONE, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (81 of 100).

Will SIBN stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +25.3% from the last close, and Ticker Nerd's factor model ranks SI-BONE, Inc. 72 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SIBN stock forecast for 2030?

No analyst covering SI-BONE, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SIBN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $32 over the next 12 months.

How has SIBN stock performed over the past year?

SI-BONE, Inc. returned +27.6% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SI-BONE, Inc. do?

Si-Bone Inc. is a prominent medical device company specializing in the development and commercialization of minimally invasive surgical implants for the treatment of sacroiliac joint dysfunction.

What is the latest news on SIBN?

The most recent item we track (Zacks Investment Research, 6 Aug 2026): "Does Si-Bone (SIBN) Have the Potential to Rally 38.58% as Wall Street Analysts Expect?". Zacks reports that the consensus price target for Si-Bone (SIBN) implies roughly 38.6% upside potential, while noting that price targets are generally not highly reliable. The article points to an upward trend in earnings estimate revisions as a potential positive indicator for the stock in the near term.

Company

About SI-BONE, Inc.

Si-Bone Inc. is a prominent medical device company specializing in the development and commercialization of minimally invasive surgical implants for the treatment of sacroiliac joint dysfunction. Known for its iFuse Implant System, the company's primary product aims to alleviate pain and improve mobility in patients suffering from lower back issues. Si-Bone Inc. plays a crucial role in the healthcare sector, particularly within the orthopedic and spinal surgery industries. The company focuses on innovation in surgical technologies and techniques, aiming to offer safer and more effective alternatives to traditional procedures. With a strong emphasis on clinical research and education for healthcare providers, Si-Bone Inc. contributes significantly to advancing patient outcomes. Catering primarily to hospitals and surgical centers, the firm maintains a dynamic presence in both domestic and international markets. Headquartered in Santa Clara, California, Si-Bone Inc.'s innovative solutions continue to influence the evolving landscape of healthcare technology and patient care.

CEO Ms. Laura A. Francis MBA · 376 employees · United States · https://si-bone.com